Although initially given as replacement therapy for patients with primary and secondary immunodeficiency states, intravenous immunoglobulin (IVIg) has proven to be effective in the treatment of various autoimmune and inflammatory disorders. This success has led to a dramatic increase in the use of IVIg, with its use as an antiinflammatory agent now vastly surpassing its use in the treatment of immunodeficiencies. Even so, the basis for the antiinflammatory activity of IVIg remains unclear.
Search results for: Novartis
Biosimilar Drugs Face Challenges to Reach the U.S. Market
To date, the FDA has not approved a biosimilar product. In its own discussion of the merits and obstacles to biosimilar drugs, the ACR sponsored a panel session titled, “Biosimilar Products in the U.S. Market: Fact or Fiction?” at the 2011 ACR/ARHP Annual Scientific Meeting here in November.
Unexpected Benefits of Bisphosphonates after Hip Fracture
Recent trials show this bisphosphonates can reduce subsequent hip fractures and mortality, while remaining cost effective.
Drug Updates: Apremilast, Belimumab, and More
Information on new approvals and medication safety
Drug Updates
Information on new approvals and medication safety
Drug Updates
Information on New Approvals and Medication Safety
Drug UPDATES
Information on New Approvals and Medication Safety
Pharma awaits FDA Guidance to Navigate the Murky Waters of Ads Via the Internet and Social Media
There’s no question that direct-to-consumer (DTC) advertising of prescription drugs is a huge activity, with nearly $5 billion spent on DTC ads in 2007. There’s also no question that the Internet has a vast potential to reach consumers. But when you put DTC advertising and the Internet together, there is a potential for problems and…
Drug Updates
Information on New Approvals and Medication Safety
Drug Updates: Information on New Approvals and Medication Safety
Information on New Approvals and Medication Safety